References
- Aken, H.V., Bode, C.B., Darius, H., Diehm, C., Encke, A., Gulba, D.C., Haas, S., Haccke, W., Puhl, W., Quante, M., Riess, H., Scharf, R., Schellong, S., Schror, K., Schulte, K.-L. and Tebbe, U. (2001). Anticoagulation: The present and future. Clin. Appl. Thrombo. Hemost., 7, 195-204 https://doi.org/10.1177/107602960100700303
- Alpert, J.S. and Dalen, J.E. (1994). Epidemiology and natural history of venous thromboembolism. Prog. Cardiovasc. Dis., 36, 417-422 https://doi.org/10.1016/S0033-0620(94)80050-2
- Cines, D.B., Rauova, L., Arepally, G., Reilly, M.P., McKenzie, S.E., Sachais, B.S. and Poncz, M. (2007). Heparininduced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J. Clin. Apher., 22, 31-36 https://doi.org/10.1002/jca.20109
- Gonze, M.D., Salartash, K., Sternbergh III, W.C., Baughman R.A., Leone-Bay, A. and Money, S.R. (2000). Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation, 101, 2658-2661 https://doi.org/10.1161/01.CIR.101.22.2658
- Ginsberg, J.S. (1999). Thromboembolism and pregnancy. Thromb. Haemost., 82, 620-625 https://doi.org/10.1055/s-0037-1615888
- Hirsh, J. and Fuster, V. (1994). Guide to anticoagulant therapy, Part 1: heparin. Circulation, 89, 14449-1468
- Hirsh, J. (2003). Current anticoagulant therapy-unmet clinical needs. Throm. Res., 109, S1-S8 https://doi.org/10.1016/S0049-3848(03)00250-0
- Hull, R., Delmore, T., Carter, C., Hirsh, J., Genton, E., Gent, M., Turpie, G. and McLaughlin, D. (1982). Adjusted subcutaneous heparin versus warfarin sodium in the longterm treatment of venous thrombosis. N. Engl. J. Med., 306, 189-194 https://doi.org/10.1056/NEJM198201283060401
- Kim, S.K., Vaishali, B., Lee, E., Lee, S., Lee, Y.K., Kumar, T.S., Moon, H.T. and Byun, Y. (2006). Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb. Res., 117, 419-427 https://doi.org/10.1016/j.thromres.2005.03.027
- Lee, Y., Moon, H.T. and Byun, Y. (1998). Preparation of slightly hydrophobic heparin derivatives which can be used for solvent casting in polymeric formulation. Thromb. Res., 92, 149-156 https://doi.org/10.1016/S0049-3848(98)00124-8
- Lee, Y., Nam, J.H., Shin, H.C. and Byun, Y. (2001). Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation, 104, 3116-3120 https://doi.org/10.1161/hc5001.100627
- Lee, Y.K., Kim, S.K., Lee, D.Y., Lee, S., Kim, C.Y., Shin, H.C. and Moon, H.T. (2006). Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. J. Control Release, 111, 290-298 https://doi.org/10.1016/j.jconrel.2005.12.011
- Malkov, D., Wang, H., Dinh, S., Steven, D. and Gomez-Orellana, I. (2002). Pathway of oral absorption of heparin with sodium N-(8-(2 hydroxybenzoyl)amino) caprylate. Pharm. Res.. 19, 1180-1184 https://doi.org/10.1023/A:1019802310702
- Mark, D.G., Jeffrey, D.M. and Andrea, L.B. (1998). Orally administered heparin for preventing deep venous thrombosis. Am. J. Surg., 176, 176-178
- Menajovsky, L.B. (2005). Heparin-induced thrombocytopenia: clinical manifestations and management. Am. J. Med., 118(Suppl. 8A), 21S-30S
- Strandness, D.E. Jr. (2001). Anticoagulant therapy: Current status and shortcomings. Seminars in Interventional Radiology, 18, 113-118
- Wolford, S.T., Schroer, R.A., Gohs, F.X., Gallo, P.P., Brodeck, M., Falk, H.B. and Ruhren, R.R. (1986). Reference range data base for serum chemistry and hematology values in laboratory animals. J. Toxicol. Environ. Heal., 18, 161- 188 https://doi.org/10.1080/15287398609530859
- 김충용, 이현숙, 한수철, 허정두, 하창수, 권명상, 정문구 (2004). Cynomolgus monkey에 있어 혈액학 및 혈액생화학적 지표. 한국실험동물학회지, 20, 44-48
- 정영미 (2006). 항응고제치료에 사용되는 약물. 병원약사회지, 23, 5-11